GlassScriptPhysician profile
Kunjan A Bhatt
NPI 1770668758
$323,881.57
in general payments reported to CMS, 2019-2025
37 companies · $123K in 2025
The $123K reported for 2025 was more than what 98% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58K · 2020: $29K · 2021: $17K · 2022: $23K · 2023: $46K · 2024: $29K · 2025: $123K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $96K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $76K · Food and Beverage: $18K · Travel and Lodging: $8,011 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $95,770.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $75,762.50 |
| Food and Beverage | $18,074.01 |
| Travel and Lodging | $8,011.12 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $176,211.42 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Gallant |
| Pfizer INC. | $66,339.73 | 2019-2025 | |
| Bridgebio Pharma, INC. | $42,050.35 | 2025 | Attruby |
| Novartis Pharmaceuticals Corporation | $13,530.57 | 2019-2024 | |
| Cvrx, INC. | $10,393.68 | 2019-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $6,496.59 | 2020-2025 | Wainua, Brilinta, Farxiga |
| Abiomed | $2,641.41 | 2019-2025 | Impella |
| Impulse Dynamics (USA) INC. | $1,309.16 | 2021-2025 | Optimizer, Optimizer |
| Alnylam Pharmaceuticals INC. | $737.93 | 2019-2025 | Onpattro, Amvuttra |
| Actelion Pharmaceuticals US, INC. | $572.29 | 2019-2023 | Uptravi |
| Merck Sharp & Dohme LLC | $466.76 | 2021-2025 | Verquvo, Capvaxive |
| Novo Nordisk INC | $431.51 | 2024-2025 | Ozempic, Wegovy |
| Boston Scientific Corporation | $394.84 | 2019-2025 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $313.16 | 2020-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $236.28 | 2024-2025 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kunjan Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.